Clarity Pharmaceuticals (Clarity Pharmaceuticals) Interest Expense : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Clarity Pharmaceuticals's interest expense for the six months ended in Dec. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Clarity Pharmaceuticals's Operating Income for the six months ended in Dec. 2023 was $ -15.81 Mil. Clarity Pharmaceuticals's Interest Expense for the six months ended in Dec. 2023 was $ 0.00 Mil. Clarity Pharmaceuticals has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Clarity Pharmaceuticals Interest Expense Historical Data

The historical data trend for Clarity Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Interest Expense Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

Interest Expense

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial			-	-	-	-	-

Clarity Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Clarity Pharmaceuticals (OTCPK:CLRPF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Clarity Pharmaceuticals's Interest Expense for the six months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the six months ended in Dec. 2023 was $-15.81 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was $0.00 Mil.

Clarity Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Clarity Pharmaceuticals had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Clarity Pharmaceuticals Ltd has no debt.

Clarity Pharmaceuticals (Clarity Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

CU6:Australia

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.